Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 16/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | EDNRB | P24530 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4632365 | 0.92 | EDNRA (0.55) | EDNRAEDNRB | |
| Hydrochloric Acid SCHEMBL4631426 | 0.91 | EDNRA (0.54) | EDNRAEDNRB | |
| SCHEMBL3631928 | 0.90 | EDNRA (0.59) | EDNRALMNAPOLBTP53THRB | |
| SCHEMBL3801811 | 0.90 | EDNRA (0.46) | EDNRALMNAEDNRBPOLB | |
| SCHEMBL12934039 | 0.90 | EDNRA (0.45) | EDNRALMNAEDNRBPOLBTP53 | |
| SCHEMBL7081510 | 0.83 | EDNRA (0.51) | EDNRAEDNRB | |
| SCHEMBL4631400 | 0.83 | EDNRA (0.48) | EDNRAEDNRB | |
| SCHEMBL12934037 | 0.81 | EDNRA (0.50) | EDNRALMNAPOLBTP53THRB | |
| SCHEMBL12934042 | 0.81 | EDNRA (0.39) | EDNRALMNAEDNRBPOLBTP53 | |
| SCHEMBL7081513 | 0.80 | EDNRA (0.50) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863308-B2 | Substituted thiophenes | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100280086-A1 | SUBSTITUTED THIOPHENES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2009002490-A2 | FORMULATIONS OF N-(2-ACETYL-4,6-DIMETHYLPHENYL)-3-{[(3,4 DIMETHYL-5-ISOXAZOLYL)AMINO]SULFONYL}-2-THIOPHENECARBOXAMIDE | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20080317858-A1 | FORMULATIONS OF N-(2-ACETYL-4,6-DIMETHYLPHENYL)-3--2-THIOPHENECARBOXAMIDE | ENCYSIVE PHARMACEUTICALS INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080317858-A1 | FORMULATIONS OF N-(2-ACETYL-4,6-DIMETHYLPHENYL)-3--2-THIOPHENECARBOXAMIDE | ENCYSIVE PHARMACEUTICALS INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080255036-A1 | Deuterated thiophene derivatives such as d2-2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide; for modulating endothelin receptors; for treating, preventing, or ameliorating one or more symptoms of an endothelin-mediated disorder | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317858-A1 | FORMULATIONS OF N-(2-ACETYL-4,6-DIMETHYLPHENYL)-3--2-THIOPHENECARBOXAMIDE | AADAC, B3GNT2, AANAT | EDNRA 1571/4885LMNA 3763/4885EDNRB 1119/4885 |
| US-20100280086-A1 | SUBSTITUTED THIOPHENES | EDNRB, ECE1, EDNRA | EDNRA 3/4885LMNA 3120/4885EDNRB 1/4885 |
| US-20080255036-A1 | Deuterated thiophene derivatives such as d2-2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide; for modulating endothelin receptors; for treating, preventing, or ameliorating one or more symptoms of an endothelin-mediated disorder | EDNRA, EDNRB, TBXA2R | EDNRA 1/4885LMNA 3101/4885EDNRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.